Inicio>>Signaling Pathways>> PROTAC>>SIM1

SIM1

Catalog No.GC63776

SIM1 es un potente PROTAC trivalente basado en von Hippel-Lindau (VHL) capaz de degradar todos los miembros de la familia BET, con preferencia por la degradaciÓn de BRD2 (IC50 = 1,1 nM; Kd = 186 nM). SIM1 muestra una actividad anticancerÍgena sostenida.

Products are for research use only. Not for human use. We do not sell to patients.

SIM1 Chemical Structure

Cas No.: 2719051-84-8

Tamaño Precio Disponibilidad Cantidad
1mg
147,00 $
Disponible
5mg
324,00 $
Disponible
10mg
558,00 $
Disponible
25mg
1.125,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SIM1 is a potent von Hippel-Lindau (VHL)-based trivalent PROTAC capable of degradation for all BET family members, with preference for BRD2 degradation (IC50=1.1 nM; Kd=186 nM). SIM1 shows sustained anti-cancer activity[1].

SIM1 (1 nM; 30 hours; MV4-11 cells) results in measurable cellular death after 6 hours[1].SIM1 (1 µM; 4 hours; HEK293 cells) degrades BET proteins[1].SIM1 induces conformational changes upon binding to the BET protein to simultaneously engage with high avidity both its bromodomains in a cis intramolecular fashion. SIM1 engages BD1 and BD2 intramolecularly and forms a 1:1:1 ternary complex with VHL and BRD4[1].

[1]. Satomi Imaide, et al. Trivalent PROTACs enhance protein degradation through cooperativity and avidity. Biological and Medicinal Chemistry.

Reseñas

Review for SIM1

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SIM1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.